ReviewFrontiers in medicine2018
Epidermolysis Bullosa Acquisita: The 2019 Update.
Review in Frontiers in medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 1 synthesis or guideline pooled it.
- European S2k guidelines on management of autoimmune blistering diseases in children and adolescents.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Guideline
- Incidence of P200 pemphigoid: A nationwide study.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Article
- CDK7, CDK9, or CDK11 inhibition reduces neutrophil-driven inflammation and tissue damage in experimental autoimmune models.Cell communication and signaling : CCS · 2026Article
- CD19×CD3 bispecific T cell engager treatment induces remission in experimental pemphigoid disease.Molecular therapy. Advances · 2026Article
- Update on Approved Therapies for Dystrophic and Junctional Epidermolysis Bullosa.Pediatric dermatology · 2026Review
- Article
- Epidermolysis bullosa acquisita improved with use of dupilumab.JAAD case reports · 2026Article
- Rituximab for autoimmune blistering diseases in pregnancy and children: a clinical review.International journal of women's dermatology · 2026Review
- Localized Bullous Pemphigoid of the Scalp and Face with Suspected Vulvar Involvement: A Case Report.Clinical, cosmetic and investigational dermatology · 2026Article
- Article
- Meeting Report on "10th Anniversary Symposium on Inflammatory Skin Disease".JID innovations : skin science from molecules to population health · 2025Article
- Emerging Techniques in Spatial Multiomics: Fundamental Principles and Applications to Dermatology.The Journal of investigative dermatology · 2025Review
- An Exceedingly Rare Case of Mechanobullous Epidermolysis Bullosa Acquisita in a Prepubertal Child: A Review of the Clinical and Laboratory Considerations.Antibodies (Basel, Switzerland) · 2025Article
- Case report: Epidermolysis bullosa acquisita following dipeptidyl peptidase-4 inhibitor therapy and complicated by immune thrombocytopenic purpura.Frontiers in immunology · 2025Article
- Immune cell senescence in autoimmunity: implications for disease pathogenesis and therapeutic targeting.Frontiers in immunology · 2025Review
- Pemphigoid disease model systems for clinical translation.Frontiers in immunology · 2025Review
- Current Knowledge on Nail Involvement in Autoimmune Bullous Disorders.Skin appendage disorders · 2024Review
- Rituximab in the Treatment of Epidermolysis Bullosa Acquisita: A Systematic Review.The Journal of clinical and aesthetic dermatology · 2024Review
- Inhibition of interferon gamma impairs induction of experimental epidermolysis bullosa acquisita.Frontiers in immunology · 2024Article
- Spontaneous autoimmune subepidermal blistering diseases in animals: a comprehensive review.BMC veterinary research · 2023Review
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epidermolysis bullosa acquisita (EBA) is an orphan autoimmune disease. Patients with EBA suffer from chronic inflammation as well as blistering and scarring of the skin and mucous membranes. Current treatment options rely on non-specific immunosuppression, which in many cases, does not lead to a remission of treatment. Hence, novel treatment options are urgently needed for the care of EBA patients. During the past decade, decisive clinical observations, and frequent use of pre-clinical model systems have tremendously increased our understanding of EBA pathogenesis. Herein, we review all of the aspects of EBA, starting with a detailed description of epidemiology, clinical presentation, diagnosis, and current treatment options. Of note, pattern analysis via direct immunofluorescence microscopy of a perilesional skin lesion and novel serological test systems have significantly facilitated diagnosis of the disease. Next, a state-of the art review of the current understanding of EBA pathogenesis, emerging treatments and future perspectives is provided. Based on pre-clinical model systems, cytokines and kinases are among the most promising therapeutic targets, whereas high doses of IgG (IVIG) and the anti-CD20 antibody rituximab are among the most promising "established" EBA therapeutics. We also aim to raise awareness of EBA, as well as initiate basic and clinical research in this field, to further improve the already improved but still unsatisfactory conditions for those diagnosed with this condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.